Rheumatoid arthritis (RA) is a chronic inflammatory disorder and one of the most common rheumatic diseases; it is characterized by inflammation and pain in the muscles, joints, and fibrous tissue.
New therapeutic observations about the role of High Mobility Group Box 1 (HMGB1) in RA and rheumatic diseases can suggest new opportunities for a targeted therapy. HMGB1 is actively or passively released into the extracellular region during cell activation, necrosis, inflammatory responses and autoimmunity: in rheumatic diseases, extracellular HMGB1 works as alarmin triggering the immune responses. Moreover HMGB1 interacts with several receptors involved in inflammation and autoimmunity like RAGE, TLR2, and TLR4.
In active phases of RA HMGB1 levels are significantly high and this suggest that HMGB1 can be a potential biomarker for active RA. Targeting HMGB1 in RA can reduce symptoms and hopefully change the disease course.
HMGBiotech can provide comprehensive information to facilitate informed decision-making for research involving HMGB1.
Discover more about our HMBG1 proteins
Read the full articles about the studies:
https://pubmed.ncbi.nlm.nih.gov/37964313/
https://www.frontiersin.org/articles/10.3389/fimmu.2022.815257/full
